CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
68Ga-FAPi-46drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05898854
NCT05898854Phase 2Completed
CompareCT.gov

[68Ga]Ga-FAPI PET/CT: The Dagnostic Accuracy for Primary Staging and Re-staging After Chemotherapy in Patients With Gastric and Gastro-esophageal Junctional Cancer

Aalborg University Hospital·interventional·Posted Jun 12, 2023·Updated Dec 30, 2025

In Brief

A Phase 2 clinical trial evaluating 68Ga-FAPi-46 for Gastric Cancer and 2 related conditions. Completed, enrolled 20 participants across 1 site.

Detailed Summary

Twenty (n=20) patients with gastric cancer or gastro-esophageal junctional cancer will undergo FAPI PET/CTs in addition to routing diagnostic workup (including FDG PET/CT) at primary staging and restaging. The FAPI PET/CT results will be compared to conventional imaging (including FDG PET/CT) using histopathology as reference standard, and the diagnostic accuracy will be determined. FAP-immunohistochemistry will be conducted in surgical specimens. FAPI PET/CT's impact on patient management and the prognostic value of FAPI PET/CT will be evaluated.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Cancer, Gastro Esophageal Junctional Cancer, Cancer
CountriesDenmark
Collaborators--

Timeline

Phase 2CompletedFinished
202420252026
First PostedJun 12, 2023
Enrollment StartFeb 15, 2024
Primary CompletionDec 18, 2025
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 3.1 years ago

Interventions

68Ga-FAPi-46drug

Gastric or gatro-esophageal junction cancer patients undergo 68Ga-FAPi-46 PET/CT at primary staging and at restaging